Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 181 AL 195

Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease

López-Martos D, Cacciaglia R, Suárez-Calvet M, Salvadó G, Shekari M, González-Escalante A, Milà-Alomà M, Brugulat-Serrat A, Minguillon C, Tonietto M, Borroni E, Klein G, Quijano-Rubio C, Kollmorgen G, Zetterberg H, Blennow K, Gispert JD, Grau-Rivera O, Sánchez-Benavides G; ALFA study.

J Prev Alzheimers Dis. 2026 Aug;13(7):100612. doi: 10.1016/j.tjpad.2026.100612. Epub 2026 Jun 8.

Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications

Veitch DP, Miller MJ, Kanoria S, Aisen PS, Beckett LA, Green RC, Harvey DJ, Jack CR Jr, Jagust W, Lee EB, Nho K, Nosheny R, Okonkwo OC, Perrin RJ, Petersen RC, Mindt MR, Saykin AJ, Shaw LM, Toga AW, Tosun D, Landau SM, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2026 Jun;22(6):e71566. doi: 10.1002/alz.71566.

Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer's disease

Labrador-Espinosa MA, Franzmeier N, Karagianni S, Moscoso A, Schöll M.

Alzheimers Res Ther. 2026 Jun 24;18(1):154. doi: 10.1186/s13195-026-02123-3.

Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies

de Los Ángeles Fernández-Ceballos M, Prieto-González JM, Agís-Balboa RC.

Cell Mol Neurobiol. 2026 Jun 24;46(1):109. doi: 10.1007/s10571-026-01752-4.

Accelerated long-term forgetting and relevant biomarkers for early detection in preclinical Alzheimer's disease

Ohno M.

Neuroscience. 2026 Sep 11;611:124-133. doi: 10.1016/j.neuroscience.2026.06.020. Epub 2026 Jun 26.

Volumetric postmortem MRI of the medial temporal lobe in Alzheimer's disease and related disorders: methodological advances and implications for in vivo biomarker development

Salman Y, Denning AE, Schaeverbeke JM, Tomé SO, Joudiou N, Khandelwal P, Yushkevich PA, Vandenberghe R, Gallez B, Wisse LE, Hanseeuw BJ.

Neuroimage. 2026 Sep;338:122098. doi: 10.1016/j.neuroimage.2026.122098. Epub 2026 Jul 2.

Assessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: A scoping review

Huynh AL, Wrigley S, Ward D, Andrews JS, Burrell LM, Yates PA.

Ageing Res Rev. 2026 Oct;121:103246. doi: 10.1016/j.arr.2026.103246. Epub 2026 Jul 15.

Orexin, Sleep, and Cognition in Alzheimer Disease: Non-REM Oscillatory Activity and Neural Resilience

Paez A, Piñol-Ripoll G, Carnes-Vendrell A, Dakterzada F, Barbé F, Zetterberg H, Dang-Vu TT.

Neurology. 2026 Aug 11;107(3):e218307. doi: 10.1212/WNL.0000000000218307. Epub 2026 Jul 14.

The past, present, and future of Alzheimer's disease-part 3: the future

Nitrini R, Takada LT, Brucki SMD.

Arq Neuropsiquiatr. 2026 Jun;84(6):1-10. doi: 10.1055/s-0046-1824435. Epub 2026 Jul 14.

Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial

Bittner T, Lopera F, Rios-Romenets S, Schiffman C, Clayton D, Hibar D, Kollmorgen G, Dolton M, Poon V, Nguyen J, Giraldo-Chica M, Acosta-Baena N, Espinosa A, Villegas G, Muñoz C, Serna L, Alvarez S, Protas H, Luo J, Sohankar J, Chen Y, Ghisays V, Malek-Ahmadi M, Ashton NJ, Denkinger MN, Cai Y, Xu YR, Ostaszewski B, Selkoe DJ, Alexander RC, Quiroz YT, Su Y, Chen K, Doody RS, Langbaum JB, Tariot PN, Sink KM, Reiman EM.

EBioMedicine. 2026 Aug;130:106390. doi: 10.1016/j.ebiom.2026.106390. Epub 2026 Jul 17.

Neurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies

Yanagisawa D, Ohgita T, Kawashima H, Yoshikawa H, Saito H, Tooyama I, Takata K.

Pharmacol Ther. 2026 Oct;286:109084. doi: 10.1016/j.pharmthera.2026.109084. Epub 2026 Jul 19.

Biomarker-Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease-Modifying Treatments: A Consensus Statement by Belgian Experts

Van Langenhove T, Van Mossevelde S, Miatton M, De Lepeleire J, Bruffaerts R, Bier JC, Segers K, Verschraegen J, Petrovic M, Ventura M, Jedidi H, Beyer I, Mormont E, Vandenberghe R, Delva A, Gilles C, Van Weehaeghe D, Picard G, De Deyn P, Strauss M, Thiery E, Salmon E, Cypers G, Vlaemynck J, Gillis K, Versijpt J, Bjerke M, Sieben A, Hanseeuw B, Engelborghs S, Deryck O; BeDeCo members.

Eur J Neurol. 2026 Aug;33(8):e70668. doi: 10.1111/ene.70668.

Adaptive cascading artificial intelligence for Alzheimer's disease assessment: a clinically oriented narrative review and implementation framework

Hooshmandi S, Rahimi Jaberi K, Kamalov F, Nami M.

Neurol Sci. 2026 Aug 3;47(8):678. doi: 10.1007/s10072-026-09282-z.

Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study

Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, Zhang J, Chi L, Liu S, Xin J, Leng L, Wang P, Chi S, Li Y, Chen J, Zhang L, Zhang J, Ma Q, Wang X, Meng X, Nao J, Li X, Lv Y, Jia Y, Zhao Q, Liu C, Gan J, Zhu J, Song Y, Li H, Fei M, Guo X, Liu J, Peng G, Chen X, Ji Y.

Alzheimers Dement. 2026 Aug;22(8):e71702. doi: 10.1002/alz.71702.

A randomized phase 1b/2 trial of ABBV-916 in adults with early Alzheimer's disease

Lynch SY, Wang Y, Wang D, Bachhav SS, Xiong H, Boiser J, Stage E, Bannon AW, Graff O, Florian H.

Alzheimers Dement. 2026 Aug;22(8):e71715. doi: 10.1002/alz.71715.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias